UNCY Unicycive Therapeutics Inc.

2.76
-0.09  -3%
Previous Close 2.85
Open 2.81
52 Week Low 2.6
52 Week High 8.73
Market Cap $40,011,317
Shares 14,496,854
Float 8,565,788
Enterprise Value $44,654,033
Volume 201,671
Av. Daily Volume 0
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
Renazorb
Chronic kidney disease (CKD)
Phase 1
Phase 1
Phase 1 trial has been completed. Single open-label safety, tolerability, and efficacy dose-ranging trial planned and to be completed by 2H 2022. NDA filing to follow.